Mechanistic studies revealed that KYNU is activated by NRF2 signaling and that KYNU overexpression is associated with an immunosuppressive tumor microenvironment characterized by elevated tumor T-cell infiltration, including T regulatory TILs, and concordant increases in protein expression of immune checkpoint blockade-related PD1 and PD-L1 (Figure 5). The gene discussed is NFE2L2; the disease is neoplasm.